Navigation Links
Pixantrone to be Studied in Phase I/II Trial for Aggressive Multiple Sclerosis
Date:3/5/2008

Preclinical profile and potential for lower cardiac toxicity drives

investigator interest

SEATTLE, March 6 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that its investigational drug pixantrone will be studied in a multicenter phase I/II trial initiated by the Fondation Charcot Stichting, in Brussels, Belgium, which sponsors a consortium of centers involved in studying new therapies for the treatment for multiple sclerosis. This study will enroll patients with aggressive relapsing remitting (RR) or secondary progressive (SP) multiple sclerosis (MS). Mitoxantrone, a related compound which is less active in preclinical studies, has been approved by the U.S. Food and Drug Administration (FDA) for the reduction of neurological disability and/or frequency of clinical response in patients with SP MS. A phase III trial with pixantrone in relapsed aggressive non-Hodgkin's lymphoma (NHL) is near completion.

"Despite the availability of newer biologic agents, drugs such as mitoxantrone remain an important therapy in relapsing MS. Long term cardiotoxicity remains a major drawback to treating multiple sclerosis with mitoxantrone and imposes a limitation both for selection of patients and for the duration of the treatment," said R.E. Gonsette, M.D., Chairman Fondation Charcot Stichting and principal investigator of the study. "In addition to the potential for lower cardiac toxicity, preclinical studies suggest that pixantrone may provide more effective immune regulation than mitoxantrone, the only currently approved cytotoxic agent for treating MS."

The investigator-sponsored trial (IST) will enroll 20 patients in Belgium, France and Germany.

About the Study

Twenty patients with aggressive RR MS or SP MS who failed to respond to approved immunomodulatory agents (interferons, glatiramer acetate) will be included. The objectives of the study are to determine the
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
2. Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting
3. Pixantrone Shows Activity in a Preclinical Study of Experimental Autoimmune Myasthenia Gravis (EAMG)
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
6. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
7. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
10. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
11. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Aufgrund der enormen Nachfrage ... Serialisierungs-Countdown-Kalender aktualisiert, der jetzt auch die Jahre 2014 ... pharmaserialisation.com , zeigt die Serialisierungsanforderungen weltweit und ... treten. Für international tätige Unternehmen geht ... "ob", sondern darum, "wann" sie die neu in ...
(Date:9/19/2014)... , Sept. 19, 2014  Over 200 runners ... Future to Benefit the Radiation Oncology Institute (ROI), hosted ... at Golden Gate Park in San Francisco.  ... Moore , CEO of Radiation Business Solutions, "but ... have raised over $70,000 for the ROI this year. ...
(Date:9/19/2014)... -- Intarcia Therapeutics, Inc. today announced the ... candidate ITCA 650 (continuous subcutaneous delivery of exenatide) in ... at the 50 th Annual Meeting of the ... from the open-label, phase 3 FREEDOM-HBL (high baseline) trial ... with poorly controlled type 2 diabetes. The results were ...
Breaking Medicine Technology:Pharma IQ stellt weltweite Serialisierungsfristen in seinen Countdown-Kalender 2014 - 2018 2Fifth Annual 5K Run for the Future to Benefit the Radiation Oncology Institute Breaks Attendance, Donation Records 2Fifth Annual 5K Run for the Future to Benefit the Radiation Oncology Institute Breaks Attendance, Donation Records 3Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 2Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 3Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 4
... Sept. 20 Cellectis bioresearch, the specialist in ... and Helix BioService & Consultants Pvt Ltd (Helix ... for the promotion of Cellectis bioresearch,s meganuclease-based products ... young company comprised of professionals with proven expertise ...
... JOSE, Calif., Sept. 17 Teikoku Pharma USA, Inc., ... U.S. Food and Drug Administration (FDA) has accepted for ... weekly transdermal patch of Aricept®, a leading medication for ... developed the weekly Aricept(r) patch based on a license ...
Cached Medicine Technology:Cellectis bioresearch and Helix Biocon Join Forces for the Promotion of cGPS® and cGPS® Custom Kits and Cell Line Engineering Services in India 2Cellectis bioresearch and Helix Biocon Join Forces for the Promotion of cGPS® and cGPS® Custom Kits and Cell Line Engineering Services in India 3FDA Accepts Aricept® Patch (Donepezil Transdermal System) NDA for Review 2
(Date:9/19/2014)... One of the major trends in the market ... useful in different application sectors such as hard tissue ... forecast the Global Bioactive Material Market to ... period 2013-2018. According to the report, increase in aging ... market. There will be an increased number of trauma, ...
(Date:9/19/2014)... Mount Pleasant Retirement Village has partnered ... Well-Being Coach Christi Hall to campus. , Hall’s journey to ... and gaining weight as a result of years of medication. ... about nutrition. One year later she had lost 50 pounds, ... endurance and cardio. , After joining the YMCA staff, she ...
(Date:9/19/2014)... There are thousands of older women who ... and there are thousands of younger men who would love ... SeekingCougar.com now provides the world's best collection of resources ... older women, and the younger men who would like to ... these people to meet each other and establish those romantic ...
(Date:9/18/2014)... Thompson and Mathieu Nikel decided it was time to tie the ... Isaac, said there was only one choice for them – Mercy ... Thompson was an undergraduate student and needed a French tutor. She ... French and so she asked him. , Thompson is ... was 7 years old. Nikel is originally from France came ...
(Date:9/18/2014)... Dr. David A. F. Ellis is a ... of Facial Plastic and Reconstructive Surgery and a Professor ... Facial Plastic Surgery. He is recognized around the ... , Dr. Ellis will be presenting on numerous injectable ... injection techniques and various treatments for complications associated with ...
Breaking Medicine News(10 mins):Health News:Bioactive Material Market to Grow at 13.30% CAGR to 2018, Forecasts a New Research Report Available at Sandlerresearch.org 2Health News:Bioactive Material Market to Grow at 13.30% CAGR to 2018, Forecasts a New Research Report Available at Sandlerresearch.org 3Health News:Bioactive Material Market to Grow at 13.30% CAGR to 2018, Forecasts a New Research Report Available at Sandlerresearch.org 4Health News:Mount Pleasant Retirement Village Partners with Atrium Family YMCA 2Health News:Mount Pleasant Retirement Village Partners with Atrium Family YMCA 3Health News:Dating Site "SeekingCougar.com" Now Offering Tips for Younger Men Seeking Older Women 2Health News:For The First Time in Over a Decade Mercy College Alumni Marry at College 2Health News:Dr. David A. F. Ellis Has Been Invited to Speak at a Conference of the American Academy of Facial Plastic and Reconstructive Surgery in Orlando, Florida 2
... Oct. 17 Symmetry Medical Inc.,(NYSE: SMA ... global orthopedic,device industry and other medical markets, announced ... Officer, Europe effective November 1,2007. Mr. Hynes ... case facilities across Europe including the UK, Ireland,France ...
... against the facial paralysis, study finds , , WEDNESDAY, Oct. 17 ... at easing a form of facial paralysis called Bell,s palsy ... that acyclovir may not be a new, improved treatment option ... the other hand, many people afflicted with Bell,s palsy do ...
... receive failing grades , , WEDNESDAY, Oct. 17 (HealthDay News) -- ... to women,s health, a new report contends. , The report ... meets only three of 27 benchmarks for women,s health. Those ... who get regular mammograms; the percentage of women who visit ...
... Include New Research on HIV Screening, Pandemic Flu,Neonatal ... WASHINGTON, Oct. 17 More than 13,000 public,health ... to address the,nation,s top public health challenges at ... The conference will feature leading experts, researchers ...
... Oct. 17 Two health care leaders were,presented ... (MHA),Health Care Leadership Award. Terence F. Moore, president ... the award in the,category of hospital management and ... with the award in the category of patient ...
... Lumenos suite of products helps consumers manage costs and adopt healthier ... ... Anthem Blue Cross and Blue,Shield in Virginia is now offering new health ... about health,care-helping them to lead healthier lives and gain control over the ...
Cached Medicine News:Health News:Symmetry Medical Appoints John Hynes Chief Operating Officer, Europe 2Health News:Symmetry Medical Appoints John Hynes Chief Operating Officer, Europe 3Health News:Antiviral Won't Improve Bell's Palsy Outcome 2Health News:U.S. Women's Health Care Still Falls Short: Report 2Health News:U.S. Women's Health Care Still Falls Short: Report 3Health News:Thousands of Public Health Experts to Address Leading Issues at APHA Annual Meeting, Nov. 3-7 2Health News:Association Honors Health Care Leaders in Midland and Troy 2Health News:Anthem Blue Cross and Blue Shield in Virginia Introduces New Generation of Consumer Driven Health Products 2Health News:Anthem Blue Cross and Blue Shield in Virginia Introduces New Generation of Consumer Driven Health Products 3Health News:Anthem Blue Cross and Blue Shield in Virginia Introduces New Generation of Consumer Driven Health Products 4
... The Infinity AST (GOT) powder reagent ... convenience of single liquid stability to help ... provide quick result turnaround time. The patented ... reagent provides a long shelf life and ...
LCD chart display...
... are extremely delicate and if repairs are ... can easily be damaged beyond repair and ... , On the other hand, with conscientious ... have a virtually indefinite lifespan. The very ...
Mobile offers full life cycle service for Sp02 accessories that are the vital link between pulse oximeter and patient...
Medicine Products: